Skip to main content
. Author manuscript; available in PMC: 2014 Jan 30.
Published in final edited form as: J Cell Biochem. 2010 Dec 1;111(5):1160–1168. doi: 10.1002/jcb.22828

Fig. 4.

Fig. 4

LOX-PP enhances doxorubicin-induced apoptosis of Her-2/neu-driven NF639 breast cancer cells. A: Cells, pre-treated with 1 or 4 μg/ml LOX-PP for 24 h, were then treated with the indicated amounts of doxorubicin for an additional 24 h. Cell viability was determined by measuring ATP production. Data represent mean ± SD of quadruplicate samples. P values were calculated using Student’s t-test, *P <0.05. B: NF639 cells were treated with 4 μg/ml LOX-PP or water control for 24 h and subsequently with 0 or 1 μM doxorubicin for another 24 h. Apoptosis was determined by Cell Death ELISA assays as described in Figure 3B. Data represent mean ± SD of triplicate samples. P values were calculated using Student’s t-test, *P <0.05. C: NF639 cells were treated with 2 μg/ml LOX-PP and 2.5 μM doxorubicin individually or in combination as described in Figure 3C and analyzed by immunoblotting of WCEs for cleaved PARP and caspase 3 and for β-actin expression.